The Tucker Carlson Show Calley Means
22 snips
Feb 3, 2024 
Calley Means, the Founder of TrueMed, dives into the controversial use of Ozempic for weight loss, arguing it’s a band-aid on deeper metabolic issues. He critiques the influence of pharmaceutical marketing on healthcare decisions, especially regarding obesity treatments for adolescents. Means sheds light on the ethics of pharmaceutical profits, revealing troubling ties between companies and healthcare practices. The discussion challenges listeners to rethink America’s reliance on medications instead of addressing the root causes of health crises.
AI Snips
Chapters
Transcript
Episode notes
Ozempic's Core Mistake
- Ozempic treats obesity as a drug deficiency, but it's a symptom of metabolic dysfunction.
- The root problem lies in a "dirty fish tank" of environmental factors.
Soda Subsidies
- The U.S. government subsidizes soda through food stamps, contributing to poor nutrition.
- Means worked with Coca-Cola, paying groups like the NAACP to oppose removing soda from food stamps.
Medical Concerns with Ozempic
- Ozempic, while potentially helpful for weight loss, has significant medical downsides.
- These include gastrointestinal issues, stomach paralysis, potential for weight regain, and even suicidal ideation.